Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment.

about

Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment.

Item

http://www.wikidata.org/entity/Q38614739

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Nomograms predicting survival ...... erapy as first-line treatment.

@en

type

Item

label

Nomograms predicting survival ...... erapy as first-line treatment.

@en

prefLabel

Nomograms predicting survival ...... erapy as first-line treatment.

@en

P1476

Nomograms predicting survival ...... erapy as first-line treatment.

@en

P2093

Byung-Ho Nam

http://www.w3.org/2001/XMLSchema#string

Mi Jung Kim

http://www.w3.org/2001/XMLSchema#string

Min Joo Yoon

http://www.w3.org/2001/XMLSchema#string

Sook Ryun Park

http://www.w3.org/2001/XMLSchema#string

Sun Young Kim

http://www.w3.org/2001/XMLSchema#string

Young Iee Park

http://www.w3.org/2001/XMLSchema#string

P2860

Nomograms in oncology: more than meets the eye

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Global cancer statistics, 2012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.

The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer

P2888

s10120-017-0756-z

P31

scholarly article

P356

10.1007/S10120-017-0756-Z

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091290612

http://www.w3.org/2001/XMLSchema#string

P698

28828688

http://www.w3.org/2001/XMLSchema#string